Efficacy and Safety Study of Urapidil Alone or With Esmolol in Treating Acute Hypertensive Intracerebral Hemorrhage

Launched by QIANFOSHAN HOSPITAL · Oct 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of two different treatments for a condition called acute hypertensive intracerebral hemorrhage, which is bleeding in the brain due to high blood pressure. The researchers want to compare the use of a medication called urapidil alone to a combination of urapidil with another medication called esmolol. The goal is to understand which treatment might be better and to help doctors create effective treatment plans for patients experiencing this serious health issue.

To participate in this study, individuals need to be between 18 and 80 years old and have been diagnosed with a specific type of brain hemorrhage confirmed by imaging within six hours of onset. They also need to have high blood pressure when they arrive at the hospital. Participants will be asked to sign an informed consent form, meaning they agree to take part in the study and understand what it involves. It’s important to note that certain people, such as those with allergies to the medications, those who are pregnant, or those with certain medical conditions, will not be eligible to participate. If selected, participants can expect regular follow-ups and monitoring as part of the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Participants in the study of acute hypertensive intracerebral hemorrhage aged between 18 and 80 years old;
• • 2. Participants with acute intracerebral hemorrhage (basal ganglia hemorrhage \< 50ml) confirmed by imaging within 6 hours of onset;
• • 3. Participants with systolic blood pressure \> 140mmHg upon admission;
• • 4. Participants who have signed the informed consent form.
• Exclusion Criteria:
• • 1. Participants in the cerebral hemorrhage study who decline to have their disease management information collected and used and/or refuse to undergo subsequent follow-ups;
• • 2. Participants with allergies to the medication in question;
• • 3. Participants in the study of secondary cerebral hemorrhage resulting from tumors, vascular malformations, aneurysms, trauma, post-thrombolytic therapy, or cerebral arteriovenous thrombosis;
• • 4. Participants undergoing anticoagulant therapy or with coagulation disorders;
• • 5. Pregnant women;
• • 6. Participants with multiple organ failure;
• • 7. Participants deemed unsuitable for enrollment by the research staff due to other factors.